Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) Short-Term Debt repayments (2019 - 2025)

United Therapeutics' Short-Term Debt repayments history spans 7 years, with the latest figure at $400.0 million for Q2 2025.

  • For Q2 2025, Short-Term Debt repayments rose 300.0% year-over-year to $400.0 million; the TTM value through Dec 2025 reached $500.0 million, up 25.0%, while the annual FY2025 figure was $500.0 million, 25.0% up from the prior year.
  • Short-Term Debt repayments for Q2 2025 was $400.0 million at United Therapeutics, up from $100.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $800.0 million in Q1 2022 and bottomed at $100.0 million in Q4 2023.
  • The 4-year median for Short-Term Debt repayments is $100.0 million (2023), against an average of $225.0 million.
  • The largest annual shift saw Short-Term Debt repayments changed 0.0% in 2024 before it surged 300.0% in 2025.
  • A 4-year view of Short-Term Debt repayments shows it stood at $800.0 million in 2022, then tumbled by 87.5% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024, then soared by 300.0% to $400.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Short-Term Debt repayments are $400.0 million (Q2 2025), $100.0 million (Q1 2025), and $100.0 million (Q4 2024).